6 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 13 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Sensorineural Hearing Loss: new trials by email Literature Review of Sensorineural Hearing Loss trials Research Report on Sensorineural Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant Otic neural progenitors, cochlear implantation - Sensorineural Hearing Loss, Presbyacusis | Phase 1 / Phase 2 | Not yet recruiting | Rinri Therapeutics | 20 | 2027-09-01 | 2026-10-01 |
| Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial Acetyl cysteine, Normal Saline - Cisplatin-induced Ototoxicity, Sensorineural Hearing Loss | Phase 2 | Recruiting | Siriraj Hospital | 40 | 2024-12-23 | 2026-01-23 |
| A Trial of LY3056480 in Patients With SNLH LY3056480 - Sensorineural Hearing Loss | Phase 2 | Withdrawn | Audion Therapeutics BV | 2022-09-01 | 2022-08-25 | |
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss PIPE-505, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Contineum Therapeutics | 28 | 2020-10-15 | 2025-04-01 |
| FX-322 in Adults With Stable Sensorineural Hearing Loss FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses) - Sensorineural Hearing Loss, Noise Induced Hearing Loss | Phase 2 | Completed | Frequency Therapeutics | 95 | 2019-10-04 | 2023-04-27 |
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment OTO-413, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 110 | 2019-10-01 | 2022-10-27 |
| Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Valganciclovir, Simple Syrup - Cmv Congenital, CMV | Phase 2 | Terminated | Albert Park | 10 | 2018-08-31 | 2026-08-27 |
| FX-322 in Sensorineural Hearing Loss FX-322, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Frequency Therapeutics | 23 | 2018-07-03 | 2022-11-14 |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| Evaluation of a Binaural Spatialization Method for Hearing Aids Hearing Aids - Sensorineural Hearing Loss | Phase 2 / Phase 3 | Completed | Sonova AG | 40 | 2016-02-01 | 2016-10-04 |
| Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Autologous Bone Marrow Infusion - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Suspended | James Baumgartner, MD | 10 | 2015-10-01 | 2022-03-18 |
| Effectiveness of P02 Digital Hearing Aids Hearing Aids Evaluation - Hearing Loss, Bilateral, Sensorineural Hearing Loss | Phase 1 / Phase 2 | Unknown | Khon Kaen University | 100 | 2012-10-01 | 2014-04-21 |
| A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Anakinra - Sensorineural Hearing Loss, Autoimmune Inner Ear Disease | Phase 1 / Phase 2 | Completed | Andrea Vambutas | 13 | 2011-06-01 | 2018-01-10 |
Hearing Loss, Sensorineural (13) · Hearing Loss (2) · Hearing Loss, Hidden (2) · Hearing Loss, Sudden (2) · Auditory neuropathy (1) · Cytomegalovirus Infections (1) · Deafness (1) · Diabetes Mellitus (1) · Hearing Loss, Bilateral (1) · Hearing Loss, Noise-Induced (1) · Iron Metabolism Disorders (1) · Meniere Disease (1) · Optic Atrophy (1) · Ototoxicity (1) · Peptic Ulcer (1)
Ear Diseases (13) · Hearing Disorders (13) · Nervous System Diseases (13) · Neurologic Manifestations (13) · Otorhinolaryngologic Diseases (13) · Pathological Conditions, Signs and Symptoms (13) · Sensation Disorders (13) · Signs and Symptoms (13) · Hearing Loss (11) · Chemically-Induced Disorders (1) · Cranial Nerve Diseases (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Duodenal Diseases (1)
Acetylcysteine (2) · Cell- and Tissue-Based Therapy (1) · Cochlear Implantation (1) · Deferiprone (1) · Hearing Aids (1) · Interleukin 1 Receptor Antagonist Protein (1) · Metformin (1) · Saline Solution (1) · Sitagliptin Phosphate (1) · Valganciclovir (1)
Frequency Therapeutics (2) · Albert Park (1) · Andrea Vambutas (1) · Audion Therapeutics BV (1) · Contineum Therapeutics (1) · Hadassah Medical Organization (1) · James Baumgartner, MD (1) · Khon Kaen University (1) · Otonomy, Inc. (1) · Rinri Therapeutics (1) · Siriraj Hospital (1) · Sonova AG (1)
United States (8) · Thailand (2) · Israel (1) · Switzerland (1) · United Kingdom (1)
Albert Park, MD (1) · Andrea Vambutas, MD (1) · Carl LeBel, PhD (1) · David Zangen, Professor (1) · Douglas Hartley (1) · George Atiee, MD (1) · Gilles Courtois, Enginner (1) · James Baumgartner, MD (1) · Kanthong Thongyai, Master (1) · Kwanchanok Yimtae, MD (1) · Stephen Huhn, MD (1)
PMID 25133431, PMID 29457537, PMID 34301203, PMID 38415855, PMID 42479273
R33DC011827 (1), U01DC014706 (1)